Journal Home > Volume 2 , Issue 2
Infectious Medicine 2023, 2(2): 105-111 https://doi.org/10.1016/j.imj.2023.04.002
Original Article | Open Access | Issue | Published: 20 April 2023

The liver-to-spleen ratio is a risk factor predicting oxygen demand in COVID-19 patients

Show Author's Information Hiromasa Nakayasu( ),  Shogo Sakurai,  Shuichi Sugiyama,  Kotaro Shiratori,  Kohei Okawa,  Yoshihiro Kitahara,  Shingo Takahashi,  Toshihiro Masuda,  Yutaro Kishimoto,  Mika Saigusa,  Akito Yamamoto,  Taisuke Akamatsu,  Satoru Morita,  Kazuhiro Asada,  Toshihiro Shirai
Department of Respiratory Medicine, Shizuoka General Hospital, 4-27-1 Kita-Ando, Aoi, 420-0805 Shizuoka, Japan
Keywords:
COVID-19, SARS-CoV-2, Oxygen demand, The liver-to-spleen ratio, Abdominal circumference
Cite this article:
Nakayasu H, Sakurai S, Sugiyama S, et al. The liver-to-spleen ratio is a risk factor predicting oxygen demand in COVID-19 patients. Infectious Medicine, 2023, 2(2): 105-111. https://doi.org/10.1016/j.imj.2023.04.002
Download citation
EndNote(RIS)
BibTeX

287

Views

3

Downloads

Citations

0

Crossref

N/A

WoS

0

Scopus

N/A

CSCD

Abstract Full text About this article
Background

We aimed to investigate risk factors predicting oxygen demand in COVID-19 patients.

Methods

Patients admitted to Shizuoka General Hospital with COVID-19 from August 2020 to August 2021 were included. First, we divided patients into groups with and without oxygen demand. Then, we compared patients' clinical characteristics and laboratory and radiological findings to determine factors predicting oxygen demand.

Results

One hundred seventy patients with COVID-19 (aged 58±15 years, 57 females) were enrolled. Common comorbidities were cardiovascular diseases (47.6%), diabetes mellitus (28.8%), and dyslipidemia (26.5%). Elder age, higher body mass index, cardiovascular diseases, diabetes mellitus, lower lymphocyte count, albumin, hepatic attenuation value, and the liver-to-spleen ratio (L/S), higher D-dimer, aspartate aminotransferase, lactate dehydrogenase, troponin-T, C-reactive protein, KL-6, chest and abdominal circumference, and visceral fat were found in patients with oxygen demand. According to the multivariate logistic regression analysis, L/S, lymphocyte count, D-dimer, and abdominal circumference under the diaphragm were independent risk factors predicting oxygen demand in COVID-19 patients.

Conclusions

On admission, L/S, lymphocyte count, D-dimer, and abdominal circumference were predictive factors for oxygen demand. These factors may help in the appropriate triage of COVID-19 patients in the decision to admit them to the hospital.


menu
Abstract
Full text
Outline
About this article

The liver-to-spleen ratio is a risk factor predicting oxygen demand in COVID-19 patients

Show Author's information Hiromasa Nakayasu( ), Shogo Sakurai, Shuichi Sugiyama, Kotaro Shiratori, Kohei Okawa, Yoshihiro Kitahara, Shingo Takahashi, Toshihiro Masuda, Yutaro Kishimoto, Mika Saigusa, Akito Yamamoto, Taisuke Akamatsu, Satoru Morita, Kazuhiro Asada, Toshihiro Shirai
Department of Respiratory Medicine, Shizuoka General Hospital, 4-27-1 Kita-Ando, Aoi, 420-0805 Shizuoka, Japan

Abstract

Background

We aimed to investigate risk factors predicting oxygen demand in COVID-19 patients.

Methods

Patients admitted to Shizuoka General Hospital with COVID-19 from August 2020 to August 2021 were included. First, we divided patients into groups with and without oxygen demand. Then, we compared patients' clinical characteristics and laboratory and radiological findings to determine factors predicting oxygen demand.

Results

One hundred seventy patients with COVID-19 (aged 58±15 years, 57 females) were enrolled. Common comorbidities were cardiovascular diseases (47.6%), diabetes mellitus (28.8%), and dyslipidemia (26.5%). Elder age, higher body mass index, cardiovascular diseases, diabetes mellitus, lower lymphocyte count, albumin, hepatic attenuation value, and the liver-to-spleen ratio (L/S), higher D-dimer, aspartate aminotransferase, lactate dehydrogenase, troponin-T, C-reactive protein, KL-6, chest and abdominal circumference, and visceral fat were found in patients with oxygen demand. According to the multivariate logistic regression analysis, L/S, lymphocyte count, D-dimer, and abdominal circumference under the diaphragm were independent risk factors predicting oxygen demand in COVID-19 patients.

Conclusions

On admission, L/S, lymphocyte count, D-dimer, and abdominal circumference were predictive factors for oxygen demand. These factors may help in the appropriate triage of COVID-19 patients in the decision to admit them to the hospital.

Keywords: COVID-19, SARS-CoV-2, Oxygen demand, The liver-to-spleen ratio, Abdominal circumference

References(37)

[1]

X. Dong, Y.Y Cao, X.X. Lu, et al., Eleven faces of coronavirus disease 2019, Allergy 75 (7) (2020) 1699–1709, doi:10.1111/all.14289.
DOI Google Scholar
[2]

Z. Wu, J.M. McGoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention, JAMA 323 (13) (2020) 1239–1242, doi:10.1001/jama.2020.2648.
DOI Google Scholar
[3]

H. Peckham, N.M. de Gruijter, C. Raine, et al., Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ICU admission, Nat. Commun. 11 (1) (2020) 6317, doi:10.1038/s41467-020-19741-6.
DOI Google Scholar
[4]

M. Terada, H. Ohtsu, S. Saito, et al., Risk factors for severity on admission and the disease progression during hospitalization in a large cohort of patients with COVID-19 in Japan, BMJ Open 11 (6) (2021) e047007, doi:10.1136/bmjopen-2020-047007.
DOI Google Scholar
[5]

Y. Uchida, H. Uemura, S. Yamaba, et al., Significance of liver dysfunction associated with decreased hepatic CT attenuation values in Japanese patients with severe COVID-19, J. Gastroenterol. 55 (11) (2020) 1098–1106, doi:10.1007/s00535-020-01717-4.
DOI Google Scholar
[6]

G. Favre, K. Legueult, C. Pradier, et al., Visceral fat is associated to the severity of COVID-19, Metabolism 115 (2021) 154440, doi:10.1016/j.metabol.2020.154440.
DOI Google Scholar
[7]

I. Zeb, D. Li, K. Nasir, et al., Computed tomography scans in the evaluation of fatty liver disease in a population based study: the multi-ethnic study of atherosclerosis, Acad. Radiol. 19 (7) (2012) 811–818, doi:10.1016/j.acra.2012.02.022.
DOI Google Scholar
[8]

Y. Kanda, Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics, Bone Marrow Transplant 48 (3) (2013) 452–458, doi:10.1038/bmt.2012.244.
DOI Google Scholar
[9]

C. Danwang, F.T. Endomba, J.R. Nkeck, et al., A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19), Biomark. Res. 8 (2020) 37, doi:10.1186/s40364-020-00217-0.
DOI Google Scholar
[10]

M. Ou, J. Zhu, P. Ji, et al., Risk factors of severe cases with COVID-19: a metaanalysis, Epidemiol. Infect. 148 (2020) e175, doi:10.1017/S095026882000179.
DOI Google Scholar
[11]

S. Ghahramani, R. Tabrizi, K.B. Lankarani, et al., Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: a systematic review and metaanalysis, Eur. J. Med. Res. 25 (1) (2020) 30, doi:10.1186/s40001-020-00432-3.
DOI Google Scholar
[12]

A. Mazzoni, L. Salvati, L. Maggi, et al., Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent, J. Clin. Invest. 130 (9) (2020) 4694–4703, doi:10.1172/JCI138554.
DOI Google Scholar
[13]

B. Diao, C. Wang, Y. Tan, et al., Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19), Front. Immunol. 11 (2020) 827, doi:10.3389/fimmu.2020.00827.
DOI Google Scholar
[14]

S. Tavakolpour, T. Rakhshandehroo, E.X. Wei, et al., Lymphopenia during the COVID-19 infection: what it shows and what can be learned, Immunol. Lett. 225 (2020) 31–32, doi:10.1016/j.imlet.2020.06.013.
DOI Google Scholar
[15]

Y. Ouyang, J. Yin, W. Wang, et al., Downregulated gene expression spectrum and immune responses changed during the disease progression in patients with COVID-19, Clin. Infect. Dis. 71 (16) (2020) 2052–2060, doi:10.1093/cid/ciaa462.
DOI Google Scholar
[16]

M.B. Pepys, G.M. Hirschfield, C-reactive protein: a critical update, J. Clin. Invest. 111 (12) (2003) 1805–1812, doi:10.1172/JCI18921.
DOI Google Scholar
[17]

I. Garrido, R. Liberal, G. Macedo, Review article: COVID-19 and liver disease-what we know on 1st May 2020,, Aliment Pharmacol. Ther 52 (2) (2020) 267–275, doi:10.1111/apt.15813.
DOI Google Scholar
[18]

Z. Xu, L. Shi, Y. Wang, et al., Pathological findings of COVID-19 associated with acute respiratory distress syndrome, Lancet Respir. Med. 8 (4) (2020) 420–422, doi:10.1016/S2213-2600(20)30076-X.
DOI Google Scholar
[19]

S.M. Lagana, S. Kudose, A.C. Iuga, et al., Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data, Mod. Pathol. 33 (11) (2020) 2147–2155, doi:10.1038/s41379-020-00649-x.
DOI Google Scholar
[20]

P. Mehta, D.F. McAuley, M. Brown, et al., COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet 395 (10229) (2020) 1033–1034, doi:10.1016/S0140-6736(20)30628-0.
DOI Google Scholar
[21]

C. Zhang, L. Shi, F.S. Wang, Liver injury in COVID-19: management and challenges, Lancet Gastroenterol. Hepatol. 5 (5) (2020) 428–430, doi:10.1016/S2468-1253(20)30057-1.
DOI Google Scholar
[22]

J. Sun, A. Aghemo, A. Forner, et al., COVID-19 and liver disease, Liver Int 40 (6) (2020) 1278–1281, doi:10.1111/liv.14470.
DOI Google Scholar
[23]

E. Guler, N.G. Unal, A. Cinkooglu, et al., Correlation of liver-to-spleen ratio, lung CT scores, clinical, and laboratory findings of COVID-19 patients with two consecutive CT scans, Abdom. Radiol. (NY) 46 (4) (2021) 1543–1551, doi:10.1007/s00261-020-02805-y.
DOI Google Scholar
[24]

S. Singh, A Khan, Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States: a multicenter research network study, Gastroenterology 159 (2) (2020) 768–771.e3, doi:10.1053/j.gastro.2020.04.064.
DOI Google Scholar
[25]

Y. Chang, J. Jeon, T.J. Song, et al., Association between the fatty liver index and the risk of severe complications in COVID-19 patients: a nationwide retrospective cohort study, BMC Infect. Dis. 22 (1) (2022) 384, doi:10.1186/s12879-022-07370-x.
DOI Google Scholar
[26]

A.S. Meijnikman, S. Bruin, A.K. Groen, et al., Increased expression of key SARSCoV-2 entry points in multiple tissues in individuals with NAFLD, J. Hepatol. 74 (3) (2021) 748–749, doi:10.1016/j.jhep.2020.12.007.
DOI Google Scholar
[27]

A. Hussain, K. Mahawar, Z. Xia, et al., Obesity and mortality of COVID-19, Meta-analysis, Obes. Res. Clin. Pract. 14 (4) (2020) 295–300, doi:10.1016/j.orcp.2020.07.002.
DOI Google Scholar
[28]

J. Yang, J. Hu, C. Zhu, Obesity aggravates COVID-19: a systematic review and metaanalysis, J. Med. Virol. 93 (1) (2021) 257–261, doi:10.1002/jmv.26237.
DOI Google Scholar
[29]

M. Watanabe, D. Caruso, D. Tuccinardi, et al., Visceral fat shows the strongest association with the need of intensive care in patients with COVID-19, Metabolism 111 (2020) 154319, doi:10.1016/j.metabol.2020.154319.
DOI Google Scholar
[30]

Y. Yang, L. Ding, X. Zou, et al., Visceral adiposity and high intramuscular fat deposition independently predict critical illness in patients with SARS-CoV-2, Obesity (Silver Spring) 28 (11) (2020) 2040–2048, doi:10.1002/oby.22971.
DOI Google Scholar
[31]

A. Petersen, K. Bressem, J. Albrecht, et al., The role of visceral adiposity in the severity of COVID-19: highlights from a unicenter cross-sectional pilot study in Germany, Metabolism 110 (2020) 154317, doi:10.1016/j.metabol.2020.154317.
DOI Google Scholar
[32]

R. Pranata, M.A. Lim, I. Huang, et al., Visceral adiposity, subcutaneous adiposity, and severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis, Clin. Nutr. ESPEN 43 (2021) 163–168, doi:10.1016/j.clnesp.2021.04.001.
DOI Google Scholar
[33]

K. Kiernan, N.J. MacIver, The role of the adipokine leptin in immune cell function in health and disease, Front. Immunol. 11 (2020) 3656, doi:10.3389/fimmu.2020.622468.
DOI Google Scholar
[34]

V. Guglielmi, L. Colangeli, M. D’Adamo, et al., Susceptibility and severity of viral infections in obesity: lessons from influenza to COVID-19. Does leptin play a role? Int. J. Mol. Sci. 22 (6) (2021) 3183, doi:10.3390/ijms22063183.
DOI Google Scholar
[35]

K. Ohashi, R. Shibata, T. Murohara, et al., Role of anti-inflammatory adipokines in obesity-related diseases, Trends Endocrinol. Metab. 25 (7) (2014) 348–355, doi:10.1016/j.tem.2014.03.009.
DOI Google Scholar
[36]

F. Tonon, S. Di Bella, F. Giudici, et al., Discriminatory value of adiponectin to leptin ratio for COVID-19 pneumonia, Int. J. Endocrinol. 2022 (2022) 9908450, doi:10.1155/2022/9908450.
DOI Google Scholar
[37]

J.L. Kuk, T.S. Church, S.N. Blair, et al., Does measurement site for visceral and abdominal subcutaneous adipose tissue alter associations with the metabolic syndrome? Diabetes Care 29 (3) (2006) 679–684, doi:10.2337/diacare.29.03.06.dc05-1500.
DOI Google Scholar
Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Received: 11 February 2023
Revised: 02 April 2023
Accepted: 10 April 2023
Published: 20 April 2023
Issue date: June 2023

Copyright

© 2023 The Author(s). Tsinghua University Press.

Acknowledgements

None.

Rights and permissions

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Return